

Phospho-Lck (Tyr505) (A3) rabbit mAb

www.abwizbio.com

Support: info@abwizbio.com

Order: sales@abwizbio.com

Catalog: #2301


Store at: -20°C

For Research Use Only. Not For Use In Diagnostic Procedures.

Applications	Detection	Clonality	Isotype
Flow Cytometry, WB	Anti-Rabbit IgG	Monoclonal	Rabbit IgGk


Format:	Unconjugated
Cross Reactivity:	Predicted to work with mouse, rat and other homologues.
Formulation:	1X PBS, 0.02% NaN ₃ , 50% Glycerol, 0.1% BSA
Preparation:	Protein A+G
Reactivity:	Human
Recommended Usage:	1µg/mL - 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.
Immunogen:	A synthetic phospho-peptide corresponding to residues surrounding Tyr505 of human phospho Lck
Description:	<p>Lck is a member of the Src family of non-receptor tyrosine kinases and plays a major role in T cell activation. Lck activates many downstream signaling pathways including Akt/mTOR, SAPK/JNK, PLCγ1, and RAS/MAPK. Phosphorylation of Lck at Tyr394 in the catalytic domain at the ATP-binding site stabilizes the open and active form, while phosphorylation at Tyr505 in the C-terminal domain promotes the closed, inactive conformation. Multiple small-molecule drugs used to treat leukemia have been shown to target inhibition of Lck, including imatinib and dasatinib. Lck is thus a promising target for suppressing T-cell responses for the treatment of inflammatory diseases or after organ transplantation.</p>
References:	<p>Serafin V, Capuzzo G, Milani G, et al. (2017) Blood. 130: 2750-2761. Lee KC, Ouwehand I, Giannini AL, et al. (2010) Leukemia. 24: 896-900.</p>

kDa




+ – CalA

Western blot analysis of Jurkat cell extract untreated or treated with 200nM calyculin A for 30min using Phospho-Lck (Tyr505) antibody LckY505-A3 at 0.1 µg/mL. Cat. #2301.




	IgG	Treatment	Peptide Block	Median : BL1-A
	A3	IFN	Non-phos.	5166
	A3	Ctrl	Non-phos.	732
	A3	IFN	Phos.	1570
	A3	Ctrl	Phos.	601
	A3	IFN	-	7656
	A3	Ctrl	-	1104
	2' only	Ctrl	-	304

Peptide blocking flow cytometric analysis of Daudi cells secondary antibody only negative control (light blue) or untreated (red) or treated with IFN α + IL-4 + pervanadate (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-Lck (Tyr505) antibody LckY505-A3 at 1 μ g/mL. Cat. #2301.



Flow cytometric analysis of Daudi cells secondary antibody only negative control (blue) or untreated (red) or treated with IFN α + IL-4 + pervanadate (green) using Phospho-Lck (Tyr505) antibody LckY505-A3 at 1 μ g/mL. Cat. #2301.



Western blot analysis of Jurkat cell extract, untreated or treated with calyculin A using 0.1 $\mu\text{g/mL}$ Phospho-Lck (Tyr505) antibody LckY505-A3 Cat. #2301 or Company C antibody at 1 $\mu\text{g/mL}$ (manufacturer's recommended concentration) developed using the same exposure.